National Viral Hepatitis Roundtable (NVHR)’s Post

Now published | The recently published ProActive study demonstrates how #Natera's Prospera Transplant Assessment test predicted antibody-mediated rejection up to five months and T cell–mediated rejection up to two months in advance of biopsy-proven rejection. Read the full study: https://ow.ly/hrFx50S2isZ #ProsperaKidney #Transplant #ClinicalResearch #cfDNA

Thoughts on this? >> Blueprint ups Ayvakit guidance; Aurinia to advance autoimmune disease asset >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #productmarketing

Thoughts on this? >> Blueprint ups Ayvakit guidance; Aurinia to advance autoimmune disease asset >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

In the newest episode of Evaluating Biopharma, host Ben Locwin speaks with Nesredin A Mussa PhD, president of Dynamica Biologics, about handling the partnerships between the sponsor and CDMO, how small companies can manage with the enhanced regulatory demands due to the nascent nature of these therapeutic platforms, and more. Listen to the conversation: https://lnkd.in/eJjHtChd

The Pan American Health Organization strategic fund has recently released an article detailing their approach to enhance access to #Leishmaniasis medicines, including “key challenges related to inadequate quantification.” At InBios, we believe an accurate diagnosis is the first step to effective treatment. Click the link below to explore InBios’ FDA cleared rapid diagnostic test kits for leishmaniasis or find the link in the comments to read the full article from PAHO.

The GARDIAN Registry has released data on the first 26 patients: 96% with Gaucher disease Type 3 (GD3) and 4% with Type 2 (GD2). GARDIAN (Gaucher Registry for Development, Innovation, and Analysis of Neuronopathic Disease) is a global initiative by the International Gaucher Alliance (IGA). It aims to improve understanding of GD2 and GD3 by collecting personal experiences from patients and families. At Prevail Therapeutics, we celebrate the remarkable work of the IGA as we recognize the critical need to include patient and caregiver voices throughout the drug development process. By collaborating with the IGA to help support GARDIAN, we hope to develop a more authentic understanding of the patient experience that will improve current drug development efforts. Discover more about the results here: https://bit.ly/4eipC5w #GARDIANRegistry #GaucherDisease #InternationalGaucherAlliance #PatientDrivenResearch #InnovationInHealthcare

A great article by my colleague Brendan Walkden on unlocking the value chain in antibiotic development, well worth a read!

REGENXBIO has completed enrollment at the second dose level of the Phase I/II AFFINITY DUCHENNE trial in patients ages 4 to 11 years old with #Duchenne #musculardystrophy. They have reported positive interim safety and efficacy data: https://bit.ly/48dvwAC.

💶 join our crowd of investors: klick on https://lnkd.in/d_5GCSQj 💶 This morning's post included the official certificate from the United States of America's Patent Office for what is now officially known as US11,883,405B2 (PCT publication WO2018/220101). Our claim 1: "a therapeutic amount of methotrexate and a non-therapeutic amount of novobiocin", meaning a drug product of methotrexate in which novobiocin acts as a PK enhancer, amplifying the therapeutic efficacy of methotrexate in immune-mediated inflammatory diseases, like #rheumatoidarthritis(RA), #psoriasis(Pso), #crohnsdisease(CD) but also #sarcoidosis, #systemiclupus(SLE) and #systemicsclerosis(SSc)

First patient in the UK is dosed in the OATD-01 Phase 2